Pharmaceutical composition. Useful in the treatment of diseases related to the activity of jak including, for example, inflammatory disorders, autoimmune disorders, cancer and other diseases.Claim 1: a compound of formula (1) or its pharmaceutically acceptable salt； where X is n o W N or Cr6 CR4； is； and is n or CR7 C1 - 6； r1 is alkyl, cycloalkyl haloalquilo C1 - C3 - 6, 6, 6 - C3 - cicloalquil c1-3 alkyl, heterocicloalquilo 4 - 6 Members, heterocicloalquil c1-3 alkyl or 4 - six members； where the c1-3 alkyl, cycloalkyl cicloalquil C3 - 6, 6 - C1 - C3 alkyl 3Heterocicloalquilo 4-6 members, and heterocicloalquil alkyl of C1 - 3 4 - 6 each Member is optionally substituted with 1, 2, or 3 independently selected from Fluorine substituents, - Oh, - or (c1-3 alkyl), - CN, - CF3, c1-3 alkyl, - NH2, - NH (c1-3 alkyl (alkyl) - n C1 - 2, - 3) C (o) n (c1-3 alkyl) 2, - C (o) NH (c1-3 alkyl, - C (o) NH2, - C (o) o (c1-3 alkyl) - S (o) 2 (c1-3 alkyl)- S (o) 2 (cycloalkyl C3 - 6) - C (o) (cycloalkyl C3 - 6, and - C (o) (c1-3 alkyl； R2 is H or alkyl c1-3 alkyl； where the c1-3 is optionally substituted with 1, 2, or 3 substituents selected irrespective of fluoride, - Oh, - or (c1-3 alkyl), - CN, - Cf3 -, NH2, NH (c1-3 alkyl)And N - (alkyl c1-3)； 2 or R1 and R2 together with the nitrogen Atom to which they are United to form a ring heterocicloalquilo 4, 5 or 6 members； optionally replaced with 1, 2, or 3 independently selected from Fluorine substituents, - Oh, - (alkyl or c1-3) C1 alkyl, - CN, - 3, haloalq Uilo C1 - 3, - NH2, - NH (c1-3 alkyl (alkyl) - n C1 - 2, and - 3) ch2cn； R3 is H, F, CL, CN, c1-3 alkyl, - ocf3,- Cf3 or (c1-3 alkyl； R4 is H, F, CL, CN, c1-3 alkyl or alkyl c1-3)； R5 is H, F, CL, CN, c1-3 alkyl or alkyl c1-3)； R6 h, F, CL, CN, or c1-3 alkyl； and R7 is H, F, CL, - CN, - ch2cn c1-3 alkyl, - C (o) n (c1-3 alkyl) 2, - C (o) NH (c1-3 alkyl) or - C (o) NH2.Composición farmacéutica. Útiles en el tratamiento de enfermedades relacionadas con la actividad de JAK incluyend
